Treats mild to moderate dementia of the Alzheimer’s type. ANDA 90957, held by Aurobindo Pharma. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 90957 (Galantamine Hydrobromide), held by Aurobindo Pharma, was first approved by FDA on Mar 29, 2011, with 7 approved supplements and 0 published complete response letters.
Galantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2011 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Feb 2, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 2, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 19, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 26, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 29, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 12, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 29, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters